Thanks for sharing Brune. Interesting though that just recently...

Thanks for sharing Brune. Interesting though that just recently the market couldn't get enough of BOT at 13c with the Cap Raising being oversubscribed and $13m raised. I doubt these institutions were looking at only a 4c profit. That said, I do think the market in general and the likes of Petra perhaps are underestimating BOT. It would be interesting to read a more thorough analysis of theirs and see what they think about the confirmed Japanese sales and how they think these apply to the US and greater world market - particularly with this being the only new drug for axillary hyperhidrosis users in decades, and one which outperforms all others also.